<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02112578</url>
  </required_header>
  <id_info>
    <org_study_id>APS 002/2013</org_study_id>
    <secondary_id>BRA15APS002-2015</secondary_id>
    <secondary_id>U1111-1149-6768</secondary_id>
    <nct_id>NCT02112578</nct_id>
  </id_info>
  <brief_title>Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin</brief_title>
  <official_title>&quot; National, Phase III, Radomized, Double-Blind, Double -Dummy, Controlled, Parallel to Evaluate Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) Soft Gel Capsules in the Control of Acute Vertigo Symphtoms From Peripheral Origin&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apsen Farmaceutica S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apsen Farmaceutica S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Evaluation of the non inferiority of Meclin (meclizine) versus Dramin (Dimenhydrinate)
           to treat the symptoms of acute vertigo from peripheral origin after up to 4 weeks of
           treatment;

        -  Evaluation of impact on quality of life in vertigo;

        -  Compare the intensity of daytime sleepiness in the two treatment groups;

        -  Compare the efficacy of drugs in relieving each of the 10 symptoms that make up the VS;

        -  Compare the duration of treatment in both treatment groups;

        -  Compare Adehence;

        -  Compare the level of satisfaction from each group from the investigators and the
           subjects;

        -  Adverse events;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a prospective interventional study arms parallel , active -controlled , non-inferiority
      . Participants selected for the study should be of both sexes , aged over 18 years and less
      than 65, which meet all the inclusion criteria and did not fit any exclusion criteria , and
      agree to all the purposes of the study. Participants are divided into two according to the
      randomization treatment groups 1:1.

      The study should take no longer than 30 days to be completed with the amount of 6 visits (7±2
      days): V0 radomization; V1, V2, V3 andV4(FV) are Evaluation visits and One Follow up visit
      7±2 days after the Final Visit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vertigo Score (VS)</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Evaluation of non inferiority by measuring 10 symptoms of vertigo : distasia and instability when walking ; totter ; spinning sensation; tendency to fall; Continuous floating feeling ; floating sensation to change position ; floating sensation to bow down ; floating sensation when standing up ; floating sensation traveling on any means of transport; floating sensation with head movement ; floating sensation with eye movement. Each symptom is graduated in a semi -quantitative 5-point scale : 0 = no symptoms ; 1 = mild symptoms ; 2 = moderate symptoms ; 3 = strong symptoms ; 4 = very strong symptoms in all visits that the subject accomplishes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire DHI - Dizziness Handicap Inventory, validated for the Brazilian population</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Evaluation of life quality</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Stanford and Epworth Sleepiness Scale</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Evaluation of somnolence (baseline measurement)</description>
  </other_outcome>
  <other_outcome>
    <measure>Variation of the intensity of each of the 10 symptoms</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Evaluation of the variation of the intensity of each of the 10 symptoms that make up VS, along the visits</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of treatment (days from V0)</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Evaluation of the duration of tratement from each group</description>
  </other_outcome>
  <other_outcome>
    <measure>Adherence rate to treatment</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Evaluation of adherence rate from each group throughout the study</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual analogue scale (VAS) for subjects and for investigators</measure>
    <time_frame>up to 30 days</time_frame>
    <description>For the subjective assessment of the participant and investigator's research on the treatment applied in 1,2,3 visits and final (VF);</description>
  </other_outcome>
  <other_outcome>
    <measure>Participants Percentage with any symptoms classified as moderate (score ≥2)</measure>
    <time_frame>Since last Visit</time_frame>
    <description>Evaluation of participants percentage with any symptoms classified as moderate on the VS Scale on the follow-up visit, held 7 ± 2 days after the final inspection (VF).
through the study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of Adverse Events</measure>
    <time_frame>After the signature of SICF</time_frame>
    <description>Evaluation of any Adverse Event ou Serious Adverse Event recorded after the signing of the Informed Consent ( IC) and until the end of the study</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical and Physical findings</measure>
    <time_frame>After the signature of SICF</time_frame>
    <description>Evaluation of any changes in clinical / physical assessment findings since baseline</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">292</enrollment>
  <condition>Vertigo, Peripheral</condition>
  <arm_group>
    <arm_group_label>Meclizine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meclizine 25 mg, tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dimenhydrinate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dimenhydrinate 50 mg, soft Capsgel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meclizine</intervention_name>
    <description>25 mg, 3 times per day up to 30 days</description>
    <arm_group_label>Meclizine</arm_group_label>
    <other_name>Meclin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dimenhydrinate</intervention_name>
    <description>50 mg, 3 times per day up to 30 days</description>
    <arm_group_label>Dimenhydrinate</arm_group_label>
    <other_name>Dramin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged over 18 years and less than 65;

          -  Presence of vertigo episodes of vestibular origin (peripheral ) of moderate intensity
             , strong or very strong according to the VS range ;

          -  Participants who are able to swallow tablets / capsules;

          -  Participants able to understand the guidance and care of this study and cooperative ;

          -  Participants with the requisite understanding, in accordance with Good Clinical
             Practice Research Document of the Americas.

        Exclusion Criteria:

          -  Use of meclizine or dimenidrynate in the actual event or in the past 15 days;

          -  Use of alcohol in the past 48 hours;

          -  Presence of vomiting which prevent the ingestion of tablets;

          -  Pregnancy or breastfeeding;

          -  Presence of clinical condition that determines contraindication to the active
             substances : convulsions , suspected intracranial compressive processes , closed-angle
             glaucoma , prostatic adenoma with urinary disorders , liver diseases , endocrine ,
             renal, and / or uncontrolled cardiovascular , Parkinson's disease, porphyria, know
             history of hipersensibility to the Actives or Excipients from the study medications;

          -  Malignancies History , even if no evidence of active disease for less than five years
             . Those without active disease for more than five years may be included;

          -  Uncontrolled systemic arterial hypertension ( &gt; 140/90 mmHg );

          -  Decompensated diabetes mellitus (blood glucose at any time &gt; 200 mg / dL );

          -  Participants with asthma or chronic obstructive pulmonary disease;

          -  Participants making use of antihistamines with anti-vertigo effect ( betahistine,
             meclizine , diphenidol ) , drugs with antagonist calcium channel action ( cinnarizine
             , flunarizine ) , anticholinergic drugs ( metoclopramide , dimenhydrinate , meclizine
             , diphenidol , scopolamine, ondansetron, granisetron ) , antiseizure drugs ( diazepam
             , clonazepam , carbamazepine ) and other central nervous system depressants;

          -  Participants with central origin vertigo or non-vestibular;

          -  Participants with positional benign positional paroxysmal vertigo (bppv).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norton Sayeg, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CCBR SP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thainá Moraes, BSc</last_name>
    <phone>55 11 5645-5150</phone>
    <email>thaina.moraes@apsen.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinilive</name>
      <address>
        <city>Maringá</city>
        <state>Paraná</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Carlos da Silva</last_name>
      <phone>55 44 30293004</phone>
    </contact>
    <investigator>
      <last_name>Antonio Carolos da Silva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericórdia de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Alcantra</last_name>
      <phone>55 11 21767235</phone>
    </contact>
    <investigator>
      <last_name>José Eduardo Lutaif Dolci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alergoalpha</name>
      <address>
        <city>Barueri</city>
        <state>São Paulo</state>
        <zip>06454010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thainara Bisognini</last_name>
      <phone>55 11 46882251</phone>
    </contact>
    <investigator>
      <last_name>Karina Tavares</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pesquisare Saude S/S Ltda</name>
      <address>
        <city>Santo André</city>
        <state>São Paulo</state>
        <zip>09080110</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amanda Faulhaber</last_name>
      <phone>55 11 44273339</phone>
    </contact>
    <investigator>
      <last_name>Amanda Faulhaber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica de Alergia MarttiAntila</name>
      <address>
        <city>Sorocaba</city>
        <state>São Paulo</state>
        <zip>18040425</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simone Fernandes</last_name>
      <phone>55 15 35194909</phone>
    </contact>
    <investigator>
      <last_name>Martti Anton Antila</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ISPEM</name>
      <address>
        <city>São José dos Campos</city>
        <state>São Paulo</state>
        <zip>12243280</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Renata Bolsolani</last_name>
      <phone>55 12 39131789</phone>
    </contact>
    <investigator>
      <last_name>Marcio Antonio Pereira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CCBR SP</name>
      <address>
        <city>São Paulo</city>
        <zip>04063001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Norton Sayeg, PhD</last_name>
      <phone>5511 43064691</phone>
    </contact>
    <investigator>
      <last_name>Norton Sayeg, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2014</study_first_submitted>
  <study_first_submitted_qc>April 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2014</study_first_posted>
  <last_update_submitted>December 1, 2016</last_update_submitted>
  <last_update_submitted_qc>December 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vertigo, Meclizine, dimenhydrinate, Peripheral Origin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vertigo</mesh_term>
    <mesh_term>Dizziness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meclizine</mesh_term>
    <mesh_term>Dimenhydrinate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

